Apidra Aventis Pharmaceuticals Inc. - Treatment for Diabetes Mellitus
Apidra is a recombinant DNA human insulin analogue that has a more rapid onset and a shorter duration of action than regular human insulin. Apidra is used for the control of hyperglycemia in adult patients with diabetes mellitus.Posted: April 2004
Related articles
- FDA Approves Apidra SoloSTAR - a Prefilled Disposable Insulin Pen - February 26, 2009
- FDA Approves Rapid-Acting Insulin Apidra for Treatment of Children with Diabetes - October 29, 2008
- FDA Approves New Route of Administration for Rapid-Acting Apidra Providing an Additional Treatment Option for Hospitalized Diabetes Patients with High Blood Sugar Levels - June 15, 2007
Apidra (insulin glulisine) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
